Hypertrophic cardiomyopathy (HCM) represents a significant challenge in cardiology due to its complex genetic nature and the risk of sudden cardiac death. Traditional imaging and clinical markers often lack the sensitivity required for early detection of molecular changes. Consequently, the emergence of a specific microRNA panel for HCM offers a promising non-invasive path for clinicians to evaluate myocardial health and disease progression.

Identifying Molecular Markers for Cardiomyopathy

A recent comparative study examined 80 individuals to determine how circulating microRNAs distinguish HCM from other conditions like moderate arterial hypertension. Specifically, the research team analyzed 40 patients with confirmed HCM and 40 sex-matched control participants. These individuals underwent rigorous examinations, including echocardiography and real-time polymerase chain reaction (PCR). Scientists primarily focused on the expression levels of microRNA-21, microRNA-29a, and microRNA-133a to assess their discriminatory power.

The results revealed striking differences in molecular expression between the two groups. For instance, the expression of microRNA-21 increased significantly in HCM patients compared to controls. Conversely, both microRNA-29a and microRNA-133a showed marked decreases. These variations provide a molecular fingerprint that reflects the underlying pathological state of the myocardium.

Diagnostic Utility of the microRNA Panel for HCM

When evaluating diagnostic accuracy, ROC analysis confirmed the high potential of these markers. Specifically, microRNA-21 demonstrated an area under the curve (AUC) of 0.887, while microRNA-29a achieved an AUC of 0.884. Furthermore, these biomarkers exhibited high sensitivity and specificity, often exceeding 84%. Such high discriminatory ability suggests that this panel could reliably differentiate HCM from common hypertensive heart disease.

Beyond simple diagnosis, these microRNAs correlate with structural changes in the heart. Increased microRNA-21 and decreased microRNA-29a appear to serve as markers for myocardial fibrosis. Additionally, the suppression of microRNA-133a likely reflects the process of hypertrophic remodeling. Consequently, this microRNA panel for HCM could aid in risk stratification by identifying patients with more extensive tissue damage.

Future Perspectives in Clinical Practice

While these findings are promising, the researchers noted that clinical significance requires further validation. Larger prospective studies are necessary to confirm these results before widespread adoption in clinical labs. However, the study clearly highlights that molecular profiling provides insights into the fibrotic and hypertrophic processes that traditional imaging might miss.

FAQ

How does the microRNA panel for HCM assist in diagnosis?

The panel measures specific molecular signals (miR-21, -29a, -133a) in the plasma. High levels of miR-21 combined with low levels of miR-29a and miR-133a help clinicians identify HCM with high sensitivity and distinguish it from simple hypertension.

What is the link between these microRNAs and heart fibrosis?

Research indicates that the upregulation of miR-21 and the downregulation of miR-29a are closely associated with myocardial fibrosis. These changes reflect the biological pathways responsible for collagen deposition and tissue scarring in the heart.

Are these biomarkers ready for routine clinical use?

Currently, they are considered potential auxiliary markers. While they show excellent diagnostic accuracy in research settings, they require validation in larger, diverse patient populations before becoming a standard part of routine clinical guidelines.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Tashina EI et al. Integrative Assessment of the Diagnostic Significance of the microRNA (-21, -29a, -133a) Panel in Patients With Hypertrophic Cardiomyopathy in Comparison With the Control Group. Kardiologiia. 2026 Feb 11. doi: 10.18087/cardio.2026.1.n3127. PMID: 41671021.

2. Perera GUN et al. Circulating microRNAs in predicting fibrosis in hypertrophic cardiomyopathy: A systematic review. World J Cardiol. 2025;17(5):267-279.

3. Li J et al. Circulating microRNA as promising biomarkers in hypertrophic cardiomyopathy: can advanced cardiac magnetic resonance unlock new insights in research? Front Cardiovasc Med. 2024;11:1456789.